OBJECTIVES: To review pulmonary complications of common variable immunodeficiency (CVID) and summarize data available on the use of replacement antibody treatment to protect against lung changes. DATA SOURCES: Relevant articles regarding CVID and pulmonary disease identified from PubMed and reference lists of review articles. STUDY SELECTION: Key articles were selected by the authors. RESULTS: Patients with CVID often develop acute sinopulmonary infections that can lead to chronic airway inflammation, which can produce substantial morbidity and mortality. Replacement immunoglobulin treatment significantly reduces the reoccurrence of lower airway infections, but the effect on the development of chronic lung damage is not yet clear. Screening examinations, such as pulmonary function testing and high-resolution computed tomography of the chest, can be used to evaluate pulmonary status. Patients with abnormal findings may benefit from more aggressive treatment, including larger doses of immune globulin and the use of prophylactic antibiotics. CONCLUSIONS: Pulmonary complications present a significant comorbidity in CVID; monitoring may indicate which patients require more aggressive treatment.
OBJECTIVES: To review pulmonary complications of common variable immunodeficiency (CVID) and summarize data available on the use of replacement antibody treatment to protect against lung changes. DATA SOURCES: Relevant articles regarding CVID and pulmonary disease identified from PubMed and reference lists of review articles. STUDY SELECTION: Key articles were selected by the authors. RESULTS:Patients with CVID often develop acute sinopulmonary infections that can lead to chronic airway inflammation, which can produce substantial morbidity and mortality. Replacement immunoglobulin treatment significantly reduces the reoccurrence of lower airway infections, but the effect on the development of chronic lung damage is not yet clear. Screening examinations, such as pulmonary function testing and high-resolution computed tomography of the chest, can be used to evaluate pulmonary status. Patients with abnormal findings may benefit from more aggressive treatment, including larger doses of immune globulin and the use of prophylactic antibiotics. CONCLUSIONS: Pulmonary complications present a significant comorbidity in CVID; monitoring may indicate which patients require more aggressive treatment.
Authors: A A J M van de Ven; P A de Jong; D P Hoytema van Konijnenburg; O A M Kessels; M Boes; E A M Sanders; S W J Terheggen-Lagro; J M van Montfrans Journal: Clin Exp Immunol Date: 2011-06-02 Impact factor: 4.330
Authors: Gaëtane C Michaud; Colleen L Channick; Chad R Marion; Robert M Tighe; James A Town; Andrew M Luks; Jeremy B Richards; Sucharita Kher; Prerna Mota; Gina Hong; Natalie E West; Craig Rackley; Luke Neilans; Josanna Rodriguez-Lopez; Hilary DuBrock; Cassie C Kennedy; Diana J Kelm; Carey C Thomson Journal: Ann Am Thorac Soc Date: 2015-09
Authors: M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330
Authors: Junmin Song; Ana Lleo; Guo Xiang Yang; Weici Zhang; Christopher L Bowlus; M Eric Gershwin; Patrick S C Leung Journal: Clin Rev Allergy Immunol Date: 2018-12 Impact factor: 8.667
Authors: Ivan J Fuss; Julia Friend; Zhiqiong Yang; Jian Ping He; Lubna Hooda; James Boyer; Liqiang Xi; Mark Raffeld; David E Kleiner; Theo Heller; Warren Strober Journal: J Clin Immunol Date: 2013-02-19 Impact factor: 8.317
Authors: Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin Journal: Int Arch Allergy Immunol Date: 2009-07-01 Impact factor: 2.749